Eleuterio Lombardo, PhD.
Eleuterio holds a Ph.D in Biochemistry and Molecular Biology from the Universidad Autónoma de Madrid (Spain) and has more than 25 years of research experience in the fields of virology, toll-like receptors, innate immunity, inflammation and stem cell biology. He developed his academic scientific career in some of the most important research institutions in Spain, and The United States (The Salk Institute and The Scripps Research Institute). He joined TiGenix (now part of Takeda) 12 years ago where, as Scientific Director, he has been responsible of generating a robust non-clinical package that supported the EU commercialization approval of Alofisel (allogeneic adipose mesenchymal stem cells (ASCs)) for the treatment of complex perianal fistulas in Crohn´s patients, and paved the clinical development of ASCs in other indications such as sepsis and rheumatoid arthritis. Eleuterio is the Project Coordinator of SEPCELL, the H2020 EU funded Consortium investigating the use of allogeneic ASCs in the treatment of sepsis (SEPCELL trial).